Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

Therapeutic area

Renal and urinary disorders – page 2

  • 591 clinical trials
  • 223 recruiting
  • 296 conditions
  • 27 countries

Conditions in this area

296 conditions with trials, the busiest first

Chronic kidney disease64Bladder cancer55Transitional cell carcinoma47Renal cell carcinoma42Bladder transitional cell carcinoma34IgA nephropathy24Acute kidney injury21Non-small cell lung cancer19Urinary tract infection19Lupus nephritis18Clear cell renal cell carcinoma17Paroxysmal nocturnal haemoglobinuria17Breast cancer14Metastatic renal cell carcinoma14End stage renal disease13Congenital cystic kidney disease12Colorectal cancer11Endometrial cancer11Hepatocellular carcinoma11Malignant melanoma11Nephrotic syndrome11Ovarian cancer11Glomerulonephritis membranous10Kidney transplant rejection10+272

Clinical trials in Renal and urinary disorders

591 trials across Europe, recruiting first

Type of trial
Recruitment status
Quick filters

591 clinical trials

Transitional cell carcinoma

Recruiting

Adjuvant Datopotamab Deruxtecan with Drug Combination in Patients with High‑Risk Muscle‑Invasive Urothelial Carcinoma

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years
  • Substances:Durvalumab
  • Sponsor:AstraZeneca AB

Transitional cell carcinoma+1

Recruiting

Study of ivonescimab plus enfortumab vedotin versus pembrolizumab plus enfortumab vedotin in previously untreated locally advanced or metastatic urothelial carcinoma

Registered drugNo placebo
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Enfortumab Vedotin
  • Sponsor:Summit Therapeutics Inc.

Bladder cancer

Recruiting

Long‑Term Follow‑Up of Mitomycin (UGN‑103) Treatment in Patients with Recurrent Low‑Grade Intermediate‑Risk Non‑Muscle Invasive Bladder Cancer

InvestigationalNo placebo
Countries:BulgariaBulgaria
  • Participants:18–64 years · 65+ years
  • Substances:Mitomycin
  • Sponsor:Urogen Pharma Ltd.

Coronary artery disease+2

Recruiting

Study of YMI024 to Reduce Inflammation in Adults with Stable Coronary Artery Disease and Elevated hsCRP

Investigational
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Sponsor:Novartis Pharma AG

Bladder transitional cell carcinoma

Recruiting

Phase III Randomized Study of Intravesical ALPHA1H as Neoadjuvant Therapy in Patients with Low- to Intermediate-Risk Non-Muscle Invasive Papillary Bladder Cancer

InvestigationalNo placebo
Countries:CzechiaCzechia
  • Participants:18–64 years · 65+ years
  • Substances:ALPHA1H
  • Sponsor:Hamlet BioPharma AB

Bladder cancer

Recruiting

Study of Enfortumab Vedotin and Pembrolizumab for Bladder Preservation in Patients with Muscle‑Invasive Bladder Cancer

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Enfortumab Vedotin
  • Sponsor:Astellas Pharma Global Development Inc.

Glomerulonephritis membranoproliferative+1

Recruiting

Effectiveness and Safety of Pegcetacoplan in Patients with C3 Glomerulopathy or Primary Immune Complex Membranoproliferative Glomerulonephritis

Registered drugNo placebo
Countries:AustriaAustria
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Pegcetacoplan
  • Sponsor:Swedish Orphan Biovitrum AB (publ)

Lupus nephritis

Recruiting

Safety and early efficacy of TranspoCART19 CAR‑T CD19 therapy in patients with refractory lupus nephritis (Phase I‑IIa)

InvestigationalNo placebo
Countries:SpainSpain
  • Participants:18–64 years
  • Substances:Transpocart19
  • Sponsor:Instituto De Investigacion Sanitaria Fundacion Jimenez Diaz

Transitional cell carcinoma metastatic

Recruiting

Safety and Antitumor Activity of PF-08634404 Alone or with Enfortumab Vedotin in Adults with Locally Advanced or Metastatic Urothelial Cancer

Registered drugNo placebo
Countries:The NetherlandsThe Netherlands
  • Participants:18–64 years · 65+ years
  • Substances:Enfortumab Vedotin
  • Sponsor:Pfizer Inc.

Transitional cell carcinoma

Recruiting

Study of TYRA-300 in Adults with Low Grade Upper Tract Urothelial Carcinoma to Assess Efficacy and Safety

InvestigationalNo placebo
Countries:BulgariaBulgaria
  • Participants:18–64 years · 65+ years
  • Substances:TYRA-300-B01
  • Sponsor:Tyra Biosciences Inc.

Renal cell carcinoma

Recruiting

Cabozantinib Monitoring for Toxicity Management in Patients with Renal Cell Carcinoma

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Cabozantinib
  • Sponsor:Centro Di Riferimento Oncologico Di Aviano

Bladder cancer

Recruiting

Durvalumab and Chemotherapy in Adults With Muscle-Invasive Bladder Cancer

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Durvalumab
  • Sponsor:AstraZeneca AB

Substances studied in this area

The therapies tested most often in Renal and urinary disorders trials.

Pembrolizumab54 clinical trialsNivolumab36 clinical trialsDapagliflozin25 clinical trialsMycophenolate Mofetil24 clinical trialsCabozantinib22 clinical trialsCisplatin22 clinical trialsIpilimumab21 clinical trialsGemcitabine20 clinical trialsSodium Chloride17 clinical trials
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.